Market Trends– category –
-
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap... -
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Boehringer Ingelheim Initiates Phase II for BI 3034701, a Novel GLP-1/GIP/NPY2 Triple Agonist, Reshaping Obesity Treatment
Life Science Daily News USA Overview Boehringer Ingelheim initiated a Phase II trial in July 2026 for BI 3034701 (NCT07662122), a groundbreaking triple agonist targeting GLP-1, GIP, and the NPY2 receptor, signaling a new direction beyond... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
Toyota Targets 1,200km Range, 10-Minute Fast Charging All-Solid-State EVs by 2028, Aiming for 9GWh Production in 2026
Top Speed Japan Overview Toyota is accelerating its plan to launch all-solid-state battery (ASSB) electric vehicles (EVs) by 2028, targeting a remarkable 745-mile (approx. 1,200km) range and 10-80% charge in just 10 minutes. Supported by... -
Greater Bay Technology Ships All-Solid-State A-Sample Battery Cells from Mass Production Line, Targeting 2026 GWh-Scale Manufacturing
Intelligent Living USA Overview Greater Bay Technology announced the shipment of its first all-solid-state A-sample battery cells from a mass-production-designed line. The company aims for gigawatt-hour (GWh) scale manufacturing by 2026,... -
CSIS Report Highlights Critical Role of Regional Networks in 21st-Century Industrial Policy: Featuring AIM Photonics
CSIS USA Overview CSIS has released a report analyzing the critical role of regional networks in 21st-century industrial policy. It emphasizes AIM Photonics (American Institute for Manufacturing Integrated Photonics), part of the Manufac...
